Compile Data Set for Download or QSAR
Report error Found 42 Enz. Inhib. hit(s) with all data for entry = 9019
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM364337(US9856274, Compound 19 | US10570156, Compound 19)
Affinity DataIC50: 10nMAssay Description:In one embodiment, the compounds provided herein were assayed for their ability to inhibit human PDE-10A. In one embodiment, the activities of the co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM364354(US9856274, Compound 36 | US10570156, Compound 36)
Affinity DataIC50: 10nMAssay Description:In one embodiment, the compounds provided herein were assayed for their ability to inhibit human PDE-10A. In one embodiment, the activities of the co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM364351(US9856274, Compound 33 | US10570156, Compound 33)
Affinity DataIC50: 10nMAssay Description:In one embodiment, the compounds provided herein were assayed for their ability to inhibit human PDE-10A. In one embodiment, the activities of the co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM364355(US9856274, Compound 37 | US10570156, Compound 37)
Affinity DataIC50: 10nMAssay Description:In one embodiment, the compounds provided herein were assayed for their ability to inhibit human PDE-10A. In one embodiment, the activities of the co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM364347(US9856274, Compound 29 | US10570156, Compound 29)
Affinity DataIC50: 10nMAssay Description:In one embodiment, the compounds provided herein were assayed for their ability to inhibit human PDE-10A. In one embodiment, the activities of the co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM364356(US9856274, Compound 38 | US10570156, Compound 38)
Affinity DataIC50: 10nMAssay Description:In one embodiment, the compounds provided herein were assayed for their ability to inhibit human PDE-10A. In one embodiment, the activities of the co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM364342(US9856274, Compound 24 | US10570156, Compound 24)
Affinity DataIC50: 10nMAssay Description:In one embodiment, the compounds provided herein were assayed for their ability to inhibit human PDE-10A. In one embodiment, the activities of the co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM364357(US9856274, Compound 39 | US10570156, Compound 39)
Affinity DataIC50: 10nMAssay Description:In one embodiment, the compounds provided herein were assayed for their ability to inhibit human PDE-10A. In one embodiment, the activities of the co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM364336(US9856274, Compound 18 | US10570156, Compound 18)
Affinity DataIC50: 10nMAssay Description:In one embodiment, the compounds provided herein were assayed for their ability to inhibit human PDE-10A. In one embodiment, the activities of the co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM364334(US9856274, Compound 16 | US10570156, Compound 16)
Affinity DataIC50: 10nMAssay Description:In one embodiment, the compounds provided herein were assayed for their ability to inhibit human PDE-10A. In one embodiment, the activities of the co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM364358(US9856274, Compound 40 | US10570156, Compound 40)
Affinity DataIC50: 10nMAssay Description:In one embodiment, the compounds provided herein were assayed for their ability to inhibit human PDE-10A. In one embodiment, the activities of the co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM364325(US9856274, Compound 7 | US10570156, Compound 7)
Affinity DataIC50: 10nMAssay Description:In one embodiment, the compounds provided herein were assayed for their ability to inhibit human PDE-10A. In one embodiment, the activities of the co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM364360(US9856274, Compound 42 | US10570156, Compound 42)
Affinity DataIC50: 10nMAssay Description:In one embodiment, the compounds provided herein were assayed for their ability to inhibit human PDE-10A. In one embodiment, the activities of the co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM364324(US9856274, Compound 6 | US10570156, Compound 6)
Affinity DataIC50: 10nMAssay Description:In one embodiment, the compounds provided herein were assayed for their ability to inhibit human PDE-10A. In one embodiment, the activities of the co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM364326(US9856274, Compound 8 | US10570156, Compound 8)
Affinity DataIC50: 10nMAssay Description:In one embodiment, the compounds provided herein were assayed for their ability to inhibit human PDE-10A. In one embodiment, the activities of the co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM364327(US9856274, Compound 9 | US10570156, Compound 9)
Affinity DataIC50: 10nMAssay Description:In one embodiment, the compounds provided herein were assayed for their ability to inhibit human PDE-10A. In one embodiment, the activities of the co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM364329(US9856274, Compound 11 | US10570156, Compound 11)
Affinity DataIC50: 10nMAssay Description:In one embodiment, the compounds provided herein were assayed for their ability to inhibit human PDE-10A. In one embodiment, the activities of the co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM364345(US9856274, Compound 27 | US10570156, Compound 27)
Affinity DataIC50: 55nMAssay Description:In one embodiment, the compounds provided herein were assayed for their ability to inhibit human PDE-10A. In one embodiment, the activities of the co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM364331(US9856274, Compound 13 | US10570156, Compound 13)
Affinity DataIC50: 55nMAssay Description:In one embodiment, the compounds provided herein were assayed for their ability to inhibit human PDE-10A. In one embodiment, the activities of the co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM364353(US9856274, Compound 35 | US10570156, Compound 35)
Affinity DataIC50: 55nMAssay Description:In one embodiment, the compounds provided herein were assayed for their ability to inhibit human PDE-10A. In one embodiment, the activities of the co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM364359(US9856274, Compound 41 | US10570156, Compound 41)
Affinity DataIC50: 55nMAssay Description:In one embodiment, the compounds provided herein were assayed for their ability to inhibit human PDE-10A. In one embodiment, the activities of the co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM364350(US9856274, Compound 32 | US10570156, Compound 32)
Affinity DataIC50: 55nMAssay Description:In one embodiment, the compounds provided herein were assayed for their ability to inhibit human PDE-10A. In one embodiment, the activities of the co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM364348(US9856274, Compound 30 | US10570156, Compound 30)
Affinity DataIC50: 55nMAssay Description:In one embodiment, the compounds provided herein were assayed for their ability to inhibit human PDE-10A. In one embodiment, the activities of the co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM364323(US9856274, Compound 5 | US10570156, Compound 5)
Affinity DataIC50: 55nMAssay Description:In one embodiment, the compounds provided herein were assayed for their ability to inhibit human PDE-10A. In one embodiment, the activities of the co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM364346(US9856274, Compound 28 | US10570156, Compound 28)
Affinity DataIC50: 55nMAssay Description:In one embodiment, the compounds provided herein were assayed for their ability to inhibit human PDE-10A. In one embodiment, the activities of the co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM364335(US9856274, Compound 17 | US10570156, Compound 17)
Affinity DataIC50: 55nMAssay Description:In one embodiment, the compounds provided herein were assayed for their ability to inhibit human PDE-10A. In one embodiment, the activities of the co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM364332(US9856274, Compound 14 | US10570156, Compound 14)
Affinity DataIC50: 55nMAssay Description:In one embodiment, the compounds provided herein were assayed for their ability to inhibit human PDE-10A. In one embodiment, the activities of the co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM364343(US9856274, Compound 25 | US10570156, Compound 25)
Affinity DataIC50: 55nMAssay Description:In one embodiment, the compounds provided herein were assayed for their ability to inhibit human PDE-10A. In one embodiment, the activities of the co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM364291(US9856274, Compound 1 | US10570156, Compound 1)
Affinity DataIC50: 55nMAssay Description:In one embodiment, the compounds provided herein were assayed for their ability to inhibit human PDE-10A. In one embodiment, the activities of the co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM364328(US9856274, Compound 10 | US10570156, Compound 10)
Affinity DataIC50: 55nMAssay Description:In one embodiment, the compounds provided herein were assayed for their ability to inhibit human PDE-10A. In one embodiment, the activities of the co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM364330(US9856274, Compound 12 | US10570156, Compound 12)
Affinity DataIC50: 300nMAssay Description:In one embodiment, the compounds provided herein were assayed for their ability to inhibit human PDE-10A. In one embodiment, the activities of the co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM364322(US9856274, Compound 4 | US10570156, Compound 4)
Affinity DataIC50: 300nMAssay Description:In one embodiment, the compounds provided herein were assayed for their ability to inhibit human PDE-10A. In one embodiment, the activities of the co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM364339(US9856274, Compound 21 | US10570156, Compound 21)
Affinity DataIC50: 300nMAssay Description:In one embodiment, the compounds provided herein were assayed for their ability to inhibit human PDE-10A. In one embodiment, the activities of the co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM364338(US9856274, Compound 20 | US10570156, Compound 20)
Affinity DataIC50: 300nMAssay Description:In one embodiment, the compounds provided herein were assayed for their ability to inhibit human PDE-10A. In one embodiment, the activities of the co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM364352(US9856274, Compound 34 | US10570156, Compound 34)
Affinity DataIC50: 300nMAssay Description:In one embodiment, the compounds provided herein were assayed for their ability to inhibit human PDE-10A. In one embodiment, the activities of the co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM364340(US9856274, Compound 22 | US10570156, Compound 22)
Affinity DataIC50: 500nMAssay Description:In one embodiment, the compounds provided herein were assayed for their ability to inhibit human PDE-10A. In one embodiment, the activities of the co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM364349(US9856274, Compound 31 | US10570156, Compound 31)
Affinity DataIC50: 500nMAssay Description:In one embodiment, the compounds provided herein were assayed for their ability to inhibit human PDE-10A. In one embodiment, the activities of the co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM364344(US9856274, Compound 26 | US10570156, Compound 26)
Affinity DataIC50: 500nMAssay Description:In one embodiment, the compounds provided herein were assayed for their ability to inhibit human PDE-10A. In one embodiment, the activities of the co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM364341(US9856274, Compound 23 | US10570156, Compound 23)
Affinity DataIC50: 500nMAssay Description:In one embodiment, the compounds provided herein were assayed for their ability to inhibit human PDE-10A. In one embodiment, the activities of the co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM364333(US9856274, Compound 15 | US10570156, Compound 15)
Affinity DataIC50: 500nMAssay Description:In one embodiment, the compounds provided herein were assayed for their ability to inhibit human PDE-10A. In one embodiment, the activities of the co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM364295(US9856274, Compound 3 | US10570156, Compound 3)
Affinity DataIC50: 500nMAssay Description:In one embodiment, the compounds provided herein were assayed for their ability to inhibit human PDE-10A. In one embodiment, the activities of the co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Human)
Sunovion Pharmaceuticals

US Patent
LigandPNGBDBM364294(US9856274, Compound 2 | US10570156, Compound 2)
Affinity DataIC50: 500nMAssay Description:In one embodiment, the compounds provided herein were assayed for their ability to inhibit human PDE-10A. In one embodiment, the activities of the co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
Go to US Patent